Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis

W. Taylor Kimberly, John F. O’Sullivan, Anjali K. Nath, Michelle Keyes, Xu Shi, Martin G. Larson, Qiong Yang, Michelle T. Long, Ramachandran Vasan, Randall T. Peterson, Thomas J. Wang, Kathleen E. Corey, Robert E. Gerszten

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


The discovery of metabolite-phenotype associations may highlight candidate biomarkers and metabolic pathways altered in disease states. We sought to identify novel metabolites associated with obesity and one of its major complications, nonalcoholic fatty liver disease (NAFLD), using a liquid chromatography–tandem mass spectrometry method. In 997 individual in Framingham Heart Study Generation 3 (FHS Gen 3), we identified an association between anandamide (AEA) and BMI. Further examination revealed that AEA was associated with radiographic hepatic steatosis. In a histologically defined NAFLD cohort, AEA was associated with NAFLD severity, the presence of nonalcoholic steatohepatitis, and fibrosis. These data highlight AEA as a marker linking cardiometabolic disease and NAFLD severity.

Original languageEnglish (US)
Article numbere92989
JournalJCI Insight
Issue number9
StatePublished - May 4 2017
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis'. Together they form a unique fingerprint.

Cite this